Deal marks the expansion into inflammatory and immune disease drug development.

Kemin has acquired Amalyte Pharmaceuticals to expand its pharmaceuticals capabilities in inflammatory and immune disease. It will operate as a separate wholly owned subsidiary.

Kemin, which was founded in 1961 to provide solutions for the agricultural and food industries, has been involved in drug development since 2004. Its pipeline is focused antibacterial, antiviral, and antiinflammatory compounds. Furthest along is Phase IIb Bacillus subtilis PB6, a bacterium against C. difficile associated diarrhea and other acute and chronic gastrointestinal diseases.

It’s other clinical candidates include a Phase II hepatitis C candidate, Phase II stomach ulcer treatment, and Phase I compounds for asthma, arthritis, and irritable bowel disorder.

Amalyte will add therapies for ulcerative colitis and allergic rhinitis, both in mid-stage trials. The company’s discovery programs reportedly focus on pulmonary and gastrointestinal indications.

Previous articleBiotech Companies Face the Key Question—Deal or No Deal?
Next articleAileron Scores $40M in Financing to Advance Preclinical Stapled Peptides